Compared to hormone receptor‐positive or HER2‐positive breast cancers, TNBC is distinguished by an aggressive clinical course, with earlier onset, high metastatic potential, and poor clinical prognosis, often manifesting as high recurrence rates and low survival rates. Here, ERBB2 is linked to breast carcinoma.